Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Currently most liver fibrosis research is performed in vivo, since suitable alternative in vitro systems which are able to recapitulate the cellular events leading to liver fibrosis are lacking. Here we aimed at generating a system containing cells representing the three key players of liver fibrosis (hepatocyte, Kupffer cells and stellate cells) and assess their response to pro-fibrotic compounds such as TGF-β1, methotrexate (MTX) and thioacetamide (TAA).</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">Human cell lines representing hepatocytes (HepaRG), Kupffer cell (THP-1 macrophages) and stellate cells (hTERT-HSC) were co-cultured using the InSphero hanging drop technology to generate scaffold-free 3D microtissues, that were treated with pro-fibrotic compounds (TGF-β1, MTX, TAA) for up to 14 days. The response of the microtissues was evaluated by determining the expression of cytokines (TNF-α, TGF-β1 and IL6), the deposition and secretion of ECM proteins and induction of gene expression of fibrosis biomarkers (e.g. αSMA). Induction of Nrf2 and Keap1, as key player of defence mechanism, was also evaluated.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">We could demonstrate that the multicellular 3D microtissue cultures could be maintained in a non-activated status, based on the low expression levels of activation markers. Macrophages were activated by stimulation with LPS and hTERT-HSC showed activation by TGF-β1. In addition, MTX and TAA elicited a fibrotic phenotype, as assessed by gene-expression and protein-deposition of ECM proteins such as collagens and fibronectin. An involvement of the antioxidant pathway upon stimulation with pro-fibrotic compounds was also observed.</AbstractText>CONCLUSION: <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Here, for the first time, we demonstrate the in vitro recapitulation of key molecular and cellular events leading to liver fibrosis: hepatocellular injury, antioxidant defence response, activation of Kupffer cells and activation of HSC leading to deposition of ECM.</AbstractText>

Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution

Extracellular Matrix and Liver Disease

Novel insights into the function and dynamics of extracellular matrix in liver fibrosis

Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment

Dynamically Remodeled Hepatic Extracellular Matrix Predicts Prognosis of Early-Stage Cirrhosis

Extracellular Matrix Metabolism and Fibrotic Disease

Extracellular matrix components indicate remodelling activity in different fibrosis stages of human non-alcoholic fatty liver disease

Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases

Liver fibrosis and extracellular matrix

Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis

Identification of miR-199a-5p, miR-214-3p and miR-99b-5p as Fibrosis-Specific Extracellular Biomarkers and Promoters of HSC Activation

Extracellular Matrix Remodeling in Chronic Liver Disease

Dynamics of compartment-specific proteomic landscapes of hepatotoxic and cholestatic models of liver fibrosis

Combining human liver ECM with topographically featured electrospun scaffolds for engineering hepatic microenvironment

Liver extracellular matrix in health and disease

Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies

The human liver matrisome - Proteomic analysis of native and fibrotic human liver extracellular matrices for organ engineering approaches

The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix

ECM1 Attenuates Hepatic Fibrosis by Interfering with Mediators of Latent TGF-β1 Activation

Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression